Martin Gleave
Vorstandsvorsitzender bei PC-TRiADD
Profil
Martin E.
Gleave is the founder of OncoGenex Pharmaceuticals, Inc. (founded in 1991) and OncoGenex Technologies, Inc. (founded in 2000).
He held the title of Chief Scientific Officer at OncoGenex Pharmaceuticals, Inc. from 2008 to 2011 and Director & Chief Scientific Officer at OncoGenex Technologies, Inc. from 2000 to 2008.
Dr. Gleave is also the founder of Sustained Therapeutics, Inc. Dr. Gleave's current jobs include Chief Executive Officer at PC-TRiADD, Research Director-Urologic Sciences Department at the University of British Columbia (since 2011), Executive Director at The Vancouver Prostate Centre, and Senior Research Scientist-Cancer Endocrinology at BC Cancer Agency.
Dr. Gleave's former jobs include Chairman at Canadian Urologic Oncology Group and Independent Director at Sirona Biochem Corp.
(from 2015 to 2017).
Dr. Gleave obtained a doctorate degree from the University of British Columbia in 1984.
Aktive Positionen von Martin Gleave
Unternehmen | Position | Beginn |
---|---|---|
University of British Columbia | Corporate Officer/Principal | - |
BC Cancer Agency
BC Cancer Agency Medical/Nursing ServicesHealth Services BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - |
The Vancouver Prostate Centre
The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services The Vancouver Prostate Centre provides prostate cancer research, treatment, and education services. Its comprehensive, in-house research program ranges from molecular biology to functional genomics, and encompasses active clinical trials, socio-behavioral studies and research into complementary and alternative medicine. The company was founded in 1998 and is headquartered in Vancouver, Canada. | Direktor/Vorstandsmitglied | - |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | Vorstandsvorsitzender | - |
Sustained Therapeutics, Inc.
Sustained Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Sustained Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in an undisclosed location. Sustained Therapeutics is developing a sustained-release drug delivery platform for managing acute and chronic pain. The Canadian company is currently conducting clinical trials for ST-01, their innovative sustained-release form of Lidocaine, for various pain indications. Patients can join their trials to experience the benefits of sustained-release Lidocaine today. The company was founded by Martin E. Gleave. | Gründer | - |
Ehemalige bekannte Positionen von Martin Gleave
Unternehmen | Position | Ende |
---|---|---|
SIRONA BIOCHEM CORP. | Direktor/Vorstandsmitglied | 13.09.2017 |
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Gründer | 01.03.2010 |
Canadian Urologic Oncology Group
Canadian Urologic Oncology Group BiotechnologyHealth Technology Canadian Urologic Oncology Group operates as a clinical research investigator network. The company is headquartered in Vancouver, Canada. | Vorsitzender | - |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Gründer | - |
Ausbildung von Martin Gleave
University of British Columbia | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
SIRONA BIOCHEM CORP. | Health Technology |
Private Unternehmen | 7 |
---|---|
OncoGenex Technologies, Inc.
OncoGenex Technologies, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Technologies, Inc. develops drugs for cancer patients. Its products are being developed to block the production of specific proteins associated with the development of treatment resistance which will increase survival time and improve the quality of life for cancer patients. The company was founded in 2000 and is headquartered in Vancouver, Canada. | Health Technology |
OncoGenex Pharmaceuticals, Inc.
OncoGenex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company, which engages develops and commercializes new cancer therapies that address treatment resistance in cancer patients. Its product include custirsen, apatorsen, and OGX-225. The company was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA. | Health Technology |
BC Cancer Agency
BC Cancer Agency Medical/Nursing ServicesHealth Services BC Cancer Agency provides healthcare services. The firm serves for hereditary cancer, indigenous cancer care, interpreters, and psychiatry. Its services include assessment and follow-up library, nutrition services, pain and symptom management, patient and family counselling, PET functional imaging, primary care, screening programs, and speech-language pathology. The company was founded on November 5, 1938 and is headquartered in Vancouver, Canada. | Health Services |
Canadian Urologic Oncology Group
Canadian Urologic Oncology Group BiotechnologyHealth Technology Canadian Urologic Oncology Group operates as a clinical research investigator network. The company is headquartered in Vancouver, Canada. | Health Technology |
The Vancouver Prostate Centre
The Vancouver Prostate Centre Miscellaneous Commercial ServicesCommercial Services The Vancouver Prostate Centre provides prostate cancer research, treatment, and education services. Its comprehensive, in-house research program ranges from molecular biology to functional genomics, and encompasses active clinical trials, socio-behavioral studies and research into complementary and alternative medicine. The company was founded in 1998 and is headquartered in Vancouver, Canada. | Commercial Services |
PC-TRiADD
PC-TRiADD Miscellaneous Commercial ServicesCommercial Services PC-TRiADD is a translational research program. It also offers pharmaceutical and biotech companies, as well as external researchers, integrated translational research services such as drug discovery, preclinical testing, tumour biology and clinical research. The company is headquartered in Vancouver, Canada. | Commercial Services |
Sustained Therapeutics, Inc.
Sustained Therapeutics, Inc. Pharmaceuticals: GenericHealth Technology Sustained Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in an undisclosed location. Sustained Therapeutics is developing a sustained-release drug delivery platform for managing acute and chronic pain. The Canadian company is currently conducting clinical trials for ST-01, their innovative sustained-release form of Lidocaine, for various pain indications. Patients can join their trials to experience the benefits of sustained-release Lidocaine today. The company was founded by Martin E. Gleave. | Health Technology |